William-MoffittCHARLOTTESVILLE, VA – July 31, 2014 – HemoSonics LLC announced today that William P. (Bill) Moffitt joined the Company as the new Chairman of the Board of Managers. Moffitt has 40 years of experience in the medical device and diagnostic industries and has spent the last 25 years developing novel technologies into products and solutions that have helped shape the industry.

In 2013, Moffitt retired as President and Chief Executive Officer of Nanosphere, Inc., a nanotechnology-based molecular diagnostics company that is commercializing a platform for earlier detection of disease and economical decentralization of complex genetic testing.  Prior to joining Nanosphere, he served as President and CEO of i-STAT Corporation, a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market.  Moffitt led i-STAT from its early research stage to commercialization and created strategic alliances with Hewlett Packard and Abbott Laboratories. Moffitt ultimately led i-STAT through its initial public offering to its acquisition by Abbott Laboratories in 2003.  From 1973 through 1989, Moffitt held increasingly responsible executive positions with Baxter Healthcare Corporation, a manufacturer and distributor of health care products, and American Hospital Supply Corporation, a diversified manufacturer and distributor of health care products, which Baxter acquired in 1985.

Moffitt currently serves as Executive Chairman of GlySure, Ltd, and as a director of privately-held medical technology companies SwipeSense, Inc. and Base 4 Innovations, Ltd.  He previously served as a director of several innovative medical technology companies and industry associations.  Moffitt holds a B.S. degree in Zoology from Duke University.

“Bill brings a wealth of practical experience in building companies and commercializing revolutionary in vitro diagnostics,” said William F. Walker, Founder and CTO of HemoSonics. “We are thrilled to have him as part of the team. With his leadership we will move rapidly to bring our novel hemostasis diagnostic to the market where it will provide physicians with the data they need to make more informed treatment decisions, thereby reducing unnecessary transfusions, improving patient outcomes and decreasing hospital costs.”